HR-8412-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Sara Jacobs (D-CA)
What it does
This bill would direct the Secretary of Health and Human Services, through the FDA Commissioner, to revise existing federal regulations governing beverages marketed to infants and toddlers. The specific regulatory changes to be made are not detailed in the bill text as introduced, suggesting the bill would grant HHS/FDA discretion to determine the scope and content of the revised rules. The bill is currently in committee in the House.
Who benefits
Infants and toddlers whose caregivers may receive clearer guidance on appropriate beverages. Parents and guardians who would have more reliable federal standards to reference when making purchasing decisions. Pediatricians and child health advocates who have called for stronger federal oversight of this product category. Manufacturers who comply with current standards and may benefit from clearer, updated rules that level the competitive playing field.
Who is hurt
Manufacturers of infant and toddler beverages whose current products may not meet revised standards, potentially requiring reformulation or relabeling at their expense. Retailers carrying non-compliant products who may face inventory disruptions. Smaller or newer beverage companies with fewer resources to absorb compliance costs. Consumers who prefer currently available products that may be reformulated or removed from shelves.
Supporters argue
Supporters argue that the infant and toddler beverage market has expanded significantly in recent years with products — such as toddler milks and flavored water drinks — that existing FDA regulations were not designed to address, leaving regulatory gaps that may expose young children to excess sugar, sodium, or other ingredients. They contend that updating these rules would give parents accurate, trustworthy labeling and bring federal standards in line with current pediatric nutrition guidance from bodies like the American Academy of Pediatrics.
Opponents argue
Opponents argue that the bill's broad, open-ended directive gives HHS and the FDA wide discretion to impose new requirements without sufficient congressional guidance, raising concerns about regulatory overreach into a product market that is already subject to general FDA food labeling rules. They contend that post-Loper Bright, any sweeping new agency rules in this space would face heightened judicial scrutiny, and that Congress should specify the precise changes it wants rather than delegating broad rulemaking authority to an executive agency.
Constitutional context
Congress regulates food and beverage labeling under the Commerce Clause (Art. I, §8, cl. 3) and the Necessary and Proper Clause. The bill delegates rulemaking authority to HHS/FDA; under Loper Bright v. Raimondo (2024), courts will now independently assess whether any resulting agency rules stay within the statutory authority Congress actually granted, rather than deferring to the agency's own interpretation.
Checks and balances
The executive branch (HHS/FDA) gains rulemaking authority to revise regulations; Congress retains oversight through the Energy and Commerce Committee, and federal courts can review any resulting rules under the post-Loper Bright independent-judgment standard.
Historical precedent
The FDA has previously updated labeling and composition rules for infant formula under the Federal Food, Drug, and Cosmetic Act, and the Infant Formula Act of 1980 established a framework for federal oversight of products in this category.